Norge - norsk - Statens legemiddelverk

merck santé s.a.s. - metforminhydroklorid - tablett, filmdrasjert - 1000 mg

Norge - norsk - Statens legemiddelverk

orifarm as - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Norge - norsk - Statens legemiddelverk

2care4 - linagliptin / metforminhydroklorid - tablett, filmdrasjert - 2.5 mg / 1000 mg

Norge - norsk - Statens legemiddelverk

paranova as - vildagliptin / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim - empagliflozin, metformin - diabetes mellitus, type 2 - legemidler som brukes i diabetes - synjardy er indisert hos voksne i alderen 18 år og eldre med type 2 diabetes mellitus som et tillegg til diett og trening for å bedre glykemisk kontroll:hos pasienter ikke kontrollert på deres maksimalt tolererte dose av metformin alene, hos pasienter som ikke kontrolleres med metformin i kombinasjon med andre glukose-senke legemidler, inkludert insulin;i pasienter som allerede blir behandlet med kombinasjonen av empagliflozin og metformin som separate tabletter.

Norge - norsk - Statens legemiddelverk

orifarm as - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Norge - norsk - Statens legemiddelverk

paranova as (1) - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Norge - norsk - Statens legemiddelverk

2care4 aps - sitagliptinfosfatmonohydrat / metforminhydroklorid - tablett, filmdrasjert - 50 mg / 1000 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Den europeiske union - norsk - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.